Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Bacterial display (or bacteria display or bacterial surface display) is a protein engineering technique used for in vitro protein evolution. Libraries of polypeptides displayed on the surface of bacteria can be screened using flow cytometry or iterative selection procedures (biopanning). This protein engineering technique allows us to link the function of a protein with the gene that encodes it. Bacterial display can be used to find target proteins with desired properties and can be used to make affinity ligands which are cell-specific. This system can be used in many applications including the creation of novel vaccines, the identification of enzyme substrates and finding the affinity of a ligand for its target protein. Bacterial display is often coupled with magnetic-activated cell sorting (MACS) or fluorescence-activated cell sorting (FACS) techniques. Competing methods for protein evolution in vitro are phage display, ribosome display, yeast display, and mRNA display. Bacteriophage display is the most common type of display system used although bacterial display is becoming increasingly popular as technical challenges are overcome. Bacterial display combined with FACS also has the advantage that it is a real-time technique.
The gene CALCA is notable for producing three distinct hormones with different effects. In addition to CGRP1, an alternative splicing encodes a precursor protein that is cleaved into calcitonin and katacalcin, which both function to reduce blood calcium levels. In addition to CGRP1, there is a second calcitonin gene-related peptide called CGRP2. This peptide is encoded by a separate gene, CALCB, but shares 90%+ homology (differing by 3 amino acids in humans). CGRP1 is traditionally considered the primary CGRP in the central and peripheral nervous system, while CGRP2 is mainly in the enteric nervous system.
=== Knapp book === The church faced internal dissent in 1991 over its decision to publish The Destiny of The Mother Church. Written and privately printed in 1943 by Bliss Knapp, former president of the Mother Church, the book suggested that Eddy was the Woman of the Apocalypse of the New Testament. Knapp and his family bequeathed $98 million to the church on condition that it publish and authorize the book by 1993; otherwise the money would go to Stanford University and the Los Angeles County Museum of Art. The church published and made the book available in Christian Science reading rooms. One senior employee was fired for failing to support the church's decision, and 18 of the 21 editorial staff of the religious journals resigned. In the end the other parties disputed that making the book available in Reading Rooms constituted authorization, and the bequest was split three ways.
Among Catholics, the positive rating decreased from 48% to 24%, and among evangelicals, from 30% to 21%. In the Northeast, traditionally a region of greater support for the president, approval fell from 49% to 33%. The survey was carried out between 10 and 11 February, with 2,007 voters from 113 cities, and has a margin of error of two percentage points. On 29 May, the study "Vida Digital de Lula", launched by the Ativaweb agency, identified that Lula lost one million followers on the social networks Instagram and Facebook. According to the study, the reasons would be the triggering of the INSS fraud scheme initiated in 2019 and the taxation of the Tax on Financial Operations (IOF). According to the portal O Antagonista, one of the reasons would be the embarrassments caused by first lady Janja. The AtlasIntel survey carried out on 30 May showed that disapproval rates of Lula's government reached the record level of 53.7%, according to the survey conducted in partnership with Bloomberg. This is the highest rate of dissatisfaction with the current administration since January 2024, due to the start of the investigations into the INSS fraud scheme. Approval of the PT government remained stable at 45.5% – in April, it was 46.1%, and in March, 44.9%. The Quaest survey released on 16 July indicated a recovery in the rating, according to the survey, because the difference between approval and disapproval was 17 points in June and 10 now. Disapproval, however, remained above approval, with 53% disapproval and 43% approval.
Sources: en.wikipedia.org
The People's Movement of Serbia (Serbian: Народни покрет Србије, romanised: Narodni pokret Srbije, abbr. NPS) is a centre-right political party in Serbia. Miroslav Aleksić has been the party's president since its reformation in August 2023. NPS previously existed from 2014 to 2017 and was also led by Aleksić, who was its only member in the National Assembly of Serbia. In October 2017, Aleksić allowed the party to be re-registered as the People's Party under the leadership of Vuk Jeremić.
April: Decree abolishing sex-based distinctions in intestate successions. July 8–10: Decree with measures repressing prostitution. July 19–22: Decree on municipal and correctional police organization, mandating sex separation in correctional facilities and assigned tasks, and measures against individuals (both sexes) deemed to have offended public morals. August 26: Olympe de Gouges publishes the Declaration of the Rights of Woman and the Female Citizen during the French Revolution, which grants citizenship to most men but does not extend the same rights to women. September 3: French Constitution of September 3, 1791, establishes crown succession laws excluding women from regency, secularizes marriage as a civil contract, and implicitly denies women citizenship. September–October: Decree specifying specific treatment for women sentenced to irons. September 28: Wives' offenses fall under husbands' civil liability. 1792
On 27 August 2025, President Luiz Inácio Lula da Silva signed Decree No. 12,595/2025, establishing the DTV+ system (also called TV 3.0) as the new standard for Brazilian free-to-air television, based on ATSC 3.0. The standard covers physical, transport, video, audio, subtitles and emergency alert layers. The preparatory phase is expected to be completed in 2025, with the first TV 3.0 transmissions beginning in the first half of 2026 in major capitals. The expansion process to reach coverage across the entire national territory is estimated to take up to 15 years. The system also incorporates internet integration, greater interactivity, accessibility and public services via the television platform. The signing of the decree followed years of studies, research, discussions and debates led by the MCom, involving companies in the sector, academics and specialists. Following the regulation, Brazilian broadcasters may begin implementing the new system. According to the minister of communications, Frederico Siqueira, the signing of the decree marked a historic moment for Brazil, strengthening free-to-air television as a democratic and popular meeting space. He highlighted that TV 3.0 will not change a central principle: free access. The new technology will modernize Brazilian digital television, offering 4K and 8K images, immersive sound, greater interactivity and integration with the internet. The goal is to provide a richer and more personalized experience for viewers, bringing free-to-air television closer to streaming services.
=== Phase 1/2 === Dexmedetomidine (BXCL-501; Igalmi; KalmPen) – α2-adrenergic receptor agonist – opioid-related disorders Ibogaine (DMX-1002; IBX-210) – various actions/unknown mechanism of action and oneirogen/hallucinogen – opioid-related disorders 5-Methoxy-2-aminoindane (MEAI; 5-MeO-AI; CMND-100) – serotonin–norepinephrine releasing agent – alcoholism PT-00114 (PT100114; TCAP-1) – corticotropin-releasing hormone (CRH) inhibitor – opioid-related disorders
Tofu is made of soybeans and is another popular food product that supplies protein. The production process of tofu varies from region to region, resulting in different kinds of tofu with a wide range of texture and taste. Other products such as soy milk, soy paste, soy oil, and fermented soy sauce are also important in Chinese cooking. There are many kinds of soybean products, including tofu skin, smoked tofu, dried tofu, and fried tofu.
Sources: en.wikipedia.org
Major historical events of the Russian Partition included the Warsaw Uprising (1794) soon after Kościuszko's victory at Racławice. It ended up in the massacre of Praga district of Warsaw, in which the Russian imperial army killed up to 20,000 civilians in reprisal or revenge, regardless of gender and age. "The whole of Praga was strewn with dead bodies, blood was flowing in streams" wrote Suvorov himself. In 1807, the victorious Napoleon formed the Duchy of Warsaw after his War of the Fourth Coalition against Prussia and Russia. The new Duchy was held in personal union by King Frederick Augustus I of Saxony. However, the Duchy was dissolved after just a few years following the 1815 Congress of Vienna, and all its territory returned to its previous rulers. The Tsarist Kingdom of Poland was established in the territory returned to Russia with the Tsar taking the title of King of Poland. The protectorate was gradually integrated into Russia over the course of the 19th century. Notwithstanding, the relentless Russian exploitation activities led to the 1830–1831 November Uprising which took place in the heartland of partitioned Poland, forming a government. Its subsequent defeat resulted in a new wave of Tsarist mass repressions and punitive actions. In 1863–1864 another insurrection, the January Uprising, broke out. This time, the Carmelite friars who helped the insurgents were sent on death marches to Siberia chained by their necks together. The January Uprising lead to the Kingdom's autonomy being drastically reduced, and its renaming as Vistula Land.
Experimental research and computer modeling indicate that the surfaces of mineral particles inside hydrothermal vents have similar catalytic properties to enzymes and are able to create simple organic molecules, such as methanol (CH3OH) and formic acid (HCO2H), out of the dissolved CO2 in the water. Additionally, the discovery of supercritical CO2 at some sites has been used to further support the theory of hydrothermal origin of life given that it can increase organic reaction rates. Its high solvation power and diffusion rate allow it to promote amino and formic acid synthesis, as well as the synthesis of other organic compounds, polymers, and the four amino acids: alanine, arginine, aspartic acid, and glycine. In situ experiments have revealed the convergence of high N2 content and supercritical CO2 at some sites, as well as evidence for complex organic material (amino acids) within supercritical CO2 bubbles. Proponents of this theory for the origin of life also propose the presence of supercritical CO2 as a solution to the "water paradox" that pervades theories on the origin of life in aquatic settings. This paradox encompasses the fact that water is both required for life and will, in abundance, hydrolyze organic molecules and prevent dehydration synthesis reactions necessary to chemical and biological evolution. Supercritical CO2, being hydrophobic, acts as a solvent that facilitates an environment conducive to dehydration synthesis.
== Research examples == In 2012 research was published where genes and proteins were found in a model organism that could not have been found without GFS because they had not been previously annotated. The planarian Schmidtea mediterranea has been used in research for over 100 years. This planarian is capable of regenerating missing body parts and is therefore emerging as potential model organism for stem cell research. Planarians are covered in mucus which aids in locomotion, in protecting them from predation, and in helping their immune system. The genome of Schmidtea mediterranea is sequenced but mostly un-annotated making it a prime candidate for genome-based peptide fingerprint scanning. When the proteins were analyzed with GFS 1,604 proteins were identified. These proteins had mostly not been annotated before they were found with GFS They were also able to find the mucous subproteome (all the genes associated with mucus production). They found that this proteome was conserved in the sister species Schmidtea mansoni. The mucous subproteome is so conserved that 119 orthologs of planarians are found in humans. Due to the similarity in these genes the planarian can now be used as a model to study mucous protein function in humans. This is relevant for infections and diseases related to mucous aberrancies such as cystic fibrosis, asthma, and other lung diseases. These genes could not have been found without GFS because they had not been previously annotated.
At menopause, breast atrophy occurs. The breasts can decrease in size when the levels of circulating estrogen decline. The adipose tissue and milk glands also begin to wither. The breasts can also become enlarged from adverse side effects of combined oral contraceptive pills. The size of the breasts can also increase and decrease in response to weight fluctuations. Physical changes to the breasts are often recorded in the stretch marks of the skin envelope; they can serve as historical indicators of the increments and the decrements of the size and volume of a woman's breasts throughout the course of her life. Breast changes during menopause are sometimes treated with hormone replacement therapy.
18 And she revealed her whorings, and she revealed her nakedness, and so I turned from her just as I turned from her sister. 19 Yet she increased her whorings, recalling the days of her childhood when she was prostituted in the land of Egypt. 20 And she lusted after her male lovers whose genitalia were the genitalia of male donkeys and their seminal emission was the seminal emission of horses. Ezekiel 23:18–20 Lexham English Bible
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.